Abstract
Murine monoclonal antibodies raised to tumor-associated antigens [1–4] and lymphoid cell receptors [5,6] have been used in clinical trials since 1980. A major complication to their use was thought to be the patient’s immune response to these xenogeneic proteins. Such immune responses or hypersensitivity reactions could result in anaphylaxis and abrogation of the antibodies’ clinical efficacy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Edwards, P.A.W. (1985) Heterogenous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. Br. J. Cancer 51:149.
Burchell, J., Durbin, H., and Taylor-Papadimitriou, J. (1983) Complexity of expression of antigenic determinants, recognised by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J. Immunol. 131:508.
Mach, J.-P., Carrel, S., et al. (1980) Tumour localisation of radiolabeled antibodies against carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (London) 248:704.
Travers, P., and Bodmer, W.F. (1984) Preparation and characterisation of monoclonal antibodies against placental alkaline phosphatase and other human trophoblast associated determinants. Int. J. Cancer 33:633.
Stevenson, G.T., and Stevenson, F.K. (1983) Treatment of lymphoid tumours with antiidiotype antibodies. Springer Semin. Immunopathol. 6:99.
Chatenoud, L., Baudrihaye, M.F., et al. (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137:830.
Ashorn, R., Ashorn, P., et al. (1985) The use of radiolabeled monoclonal antibodies to human milk fat globule membrane antigens in antibody-guided tumour imaging, and administration of therapeutic dose of labelled antibody in wide-spread ovarian carcinoma. Ann. Chir. Gynaecol. 74:5.
Epenetos, A.A., Courtenay-Luck, N.S., et al. (1984) Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment. Lancet 1:1441.
Davies, A.G., Bourne, S.P., et al. (1986) Pre-existing specific anti-mouse immunoglobulin in a patient receiving 131 I-murine monoclonal antibody for radioimmunolocalisation. Br. J. Cancer 53:289.
Schroff, R.W., Foon, K.A., et al. (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 45:879.
Courtenay-Luck, N.S., Epenetos, A.A., et al. (1987) Pre-existing human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors. Cancer Res. 47:4520.
Pimm, M.V., Perkins, A.C., et al. (1985) The characteristics of blood-bourne radiolabels and the effect of anti-mouse IgG antibodies on localisation of radiolabeled monoclonal antibody in cancer patients. J. Nucl. Med. 26:1011.
Dillman, R.O., Shawler, D.L., et al. (1983) Monoclonal antibody therapy of cutaneous T-cell lymphoma (CTCL). Blood 62(suppl 1):212.
Epenetos, A.A., Munro, A.J., et al. (1987) Antibody guided therapy of advanced ovarian cancer using intraperitoneally administered radiolabeled monoclonal antibodies. J. Clin. Oncol.
Jerne, N.K. (1974) Towards a network theory of the immune system. Ann. Immunol. (Paris) 125C:373.
Bruck, C., Sung Co, M., et al. (1986) Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc. Natl. Acad. Sci. USA 83:6578.
Zanetti, M., Glotz, D., and Rogers, J. (1986) Perturbation of the autoimmune network. J. Immunol. 137:3140.
Koprowski, H., Herlyn, D., et al. (1984) Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc. Natl. Acad. Sci. USA 81:216.
Herlyn, D., Lubeck, M., et al. (1985) Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J. Immunol. Methods 85:27.
Sears, H.F., Atkinson, B., et al. (1982) Phase-1 clinical trials of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1:726.
Chatenoud, L., Baudrihaye, M.F., et al. (1986) Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 137:830.
Lowder, J.N., Miller, R.A., et al. (1987) Suppression of anti-mouse immunoglobulin antibodies in subhuman primates receiving murine monoclonal antibodies against T cell antigens. J. Immunol. 138:401.
Miller, R.A., Oseroff, A.R., et al. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988.
Berd, D., and Mastrangelo, M.J. (1987) Effects of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T-suppressor function without depletion of the C08+ subset. Cancer Res. 47:3317.
Turk, J.L., and Parker, D. (1982) Effects of cyclophosphamide on immunological control mechanisms. Immunol. Rev. 65:99.
Neuberger, M.S., Williams, G.T., and Fox, R.O. (1984) Recombinant antibodies possessing novel effector functions. Nature 312:604.
Brown, B.A., Davis, G.L., et al. (1987) Tumor specifie genetically engineered murine/human chimeric monoclonal antibody. Cancer Res. 47:3577.
Jones, P.T., Dar, P.H., et al. (1986) Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 321:522.
Sun, L.K., Curtis, P., et al. (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc. Natl. Acad. Sci. USA 84:214.
Iris, R.F., Sze, L.L., and Saxton, R.E. (1982) Human antibody to OFA-1, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc. Natl. Acad. Sci. USA 79:5666.
Kaplan, H.S., and Olsson, L. (1980) Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc. Natl. Acad. Sci. USA 77:5429.
Sikora, K., Alderson, T., et al. (1983) Human hybridomas from patients with malignant disease. Br. J. Cancer 47:135.
Benjamin, R.J., Cobbold, S.P., et al. (1986) Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163:1539.
Sharpe, A.H., Gaulton, G.N., et al. (1984) Syngeneic monoclonal anti-idiotype can induce cellular immunity to reovirus. J. Exp. Med. 160:1195.
Skein, K.E., and Soderstrom, T. (1984) Neonatal administration of idiotype of anti-idiotype primes for protection against Escherichia coli K13 infection in mice. J. Exp. Med. 160:1001.
Uytdehaag, F.G.C.M., and Osterhaus, A.D.M.E. (1985) Induction of neutralising antibody in mice against polio virus type II with monoclonal anti-idiotypic antibody. J. Immunol. 134: 1225.
Dunn, P.L., Johnson, C.A., et al. (1987) Vaccination with syngeneic monoclonal antiidiotype protects against a tumor challenge. Immunology 60:181.
Kennedy, R.C., Dreesman, G.R., et al. (1985) Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies. J. Exp. Med. 161:1432.
Binz, H., Meier, B., and Wigzell, H. (1982) Induction or elimination of tumor-specific immunity against a chemically induced rat tumor using auto-anti-idiotypic antibodies. Int. J. Cancer 19:417–421.
Raychaudhari, S., Saeki, H., et al. (1986) Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J. Immunol. 137:1743–2000.
Raychaudhuri, S., Saeki, H., et al. (1986) Tumor specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2b). J. Immunol. 139:271–279.
Raychaudhuri, S., Saeki, Y., et al. (1987) Tumor-specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumour cells. J. Immunol. 139:2096–2102.
Zanetti, M., Sercatz, E., Salu, J. (1987) The immunology of new generation vaccines. Immunol. Today 8:18–25.
Nelson, K.A., George, E., et al. (1987) Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. J. Immunol. 139: 2110–2117.
Herlyn, D., Wettendorff, M., et al. (1987) Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc. Natl. Acad. Sci. USA 84:8055–8059.
Capron, A., Dessaint, J.P., et al. (1987) Immunity to schistosomes: Progress toward vaccine. Science 238:1065–1072.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers
About this chapter
Cite this chapter
Courtenay-Luck, N.S., Epenetos, A.A. (1990). Diversity of the human immune response to clinically used murine monoclonal antibodies. In: Goldenberg, D.M. (eds) Cancer Imaging with Radiolabeled Antibodies. Cancer Treatment and Research, vol 51. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1497-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1497-4_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8805-3
Online ISBN: 978-1-4613-1497-4
eBook Packages: Springer Book Archive